 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in UAMS Profiles by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 0 | 1 | | 2024 | 3 | 8 | 11 | | 2023 | 1 | 8 | 9 | | 2022 | 1 | 13 | 14 | | 2021 | 4 | 15 | 19 | | 2020 | 6 | 3 | 9 | | 2019 | 4 | 4 | 8 | | 2018 | 2 | 1 | 3 | | 2017 | 9 | 5 | 14 | | 2016 | 4 | 4 | 8 | | 2015 | 4 | 2 | 6 | | 2014 | 3 | 0 | 3 | | 2013 | 1 | 1 | 2 | | 2012 | 2 | 0 | 2 | | 2011 | 7 | 2 | 9 | | 2010 | 1 | 2 | 3 | | 2009 | 3 | 4 | 7 | | 2008 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2005 | 4 | 3 | 7 | | 2004 | 2 | 3 | 5 | | 2003 | 3 | 3 | 6 | | 2002 | 2 | 2 | 4 | | 2001 | 3 | 1 | 4 | | 2000 | 1 | 2 | 3 | | 1999 | 0 | 1 | 1 | | 1998 | 3 | 2 | 5 | | 1997 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles over the past ten years.
-
Biltibo EMD, Surapaneni M, Al Hadidi S, Suvannasankha A, Jayani-Kosarzycki RV. Current and Future Directions of Immunotherapies in Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473316.
-
Zhao Z, Fetse J, Mamani UF, Guo Y, Li Y, Patel P, Liu Y, Lin CY, Li Y, Mustafa B, Cheng K. Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy. Acta Biomater. 2025 Jan 24; 193:484-497.
-
Wei M, Bannout F, Dastjerdi M, Phan C, Batarseh S, Guo X, Baker N. Immunotherapy in a case of low titre GAD65 antibody-associated spectrum neurological disorders. BMJ Case Rep. 2024 Jun 13; 17(6).
-
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplant Cell Ther. 2024 Aug; 30(8):790.e1-790.e16.
-
Mohan M, Van Oekelen O, Akhtar OS, Cohen A, Parekh S. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e432204.
-
Kirkpatrick C, Lu YW. Deciphering CD4+ T cell-mediated responses against cancer. Mol Carcinog. 2024 Jul; 63(7):1209-1220.
-
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, G?llego P?rez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, H?jek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216.
-
Petroni D, B?gin P, Bird JA, Brown-Whitehorn T, Chong HJ, Fleischer DM, Gagnon R, Jones SM, Leonard S, Makhija MM, Oriel RC, Shreffler WG, Sindher SB, Sussman GL, Yang WH, Bee KJ, Bois T, Campbell DE, Green TD, Rutault K, Sampson HA, Wood RA. Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow's Milk Allergy: A Randomized Clinical Trial. JAMA Pediatr. 2024 Apr 01; 178(4):345-353.
-
Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. Oncologist. 2024 Mar 04; 29(3):200-212.
-
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024 Mar 04; 221(3).
-
Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J, Negm L, Dimayacyac JR, Chang Y, Nobre L, Ercan AB, Sanchez-Ramirez S, Sudhaman S, Edwards M, Larouche V, Samuel D, Van Damme A, Gass D, Ziegler DS, Bielack SS, Koschmann C, Zelcer S, Yalon-Oren M, Campino GA, Sarosiek T, Nichols KE, Loret De Mola R, Bielamowicz K, Sabel M, Frojd CA, Wood MD, Glover JM, Lee YY, Vanan M, Adamski JK, Perreault S, Chamdine O, Hjort MA, Zapotocky M, Carceller F, Wright E, Fedorakova I, Lossos A, Tanaka R, Osborn M, Blumenthal DT, Aronson M, Bartels U, Huang A, Ramaswamy V, Malkin D, Shlien A, Villani A, Dirks PB, Pugh TJ, Getz G, Maruvka YE, Tsang DS, Ertl-Wagner B, Hawkins C, Bouffet E, Morgenstern DA, Tabori U. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium. Cancer Discov. 2024 Feb 08; 14(2):258-273.
-
Layer JP, Shiban E, Brehmer S, Diehl CD, de Castro DG, Hamed M, Dejonckheere CS, Cifarelli DT, Friker LL, Herrlinger U, H?lzel M, Vatter H, Schneider M, Combs SE, Schmeel LC, Cifarelli CP, Giordano FA, Sarria GR, Kahl KH. Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1552-1562.
-
Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt MJ, Truger M, Mersi J, Teufel E, Han S, Haertle L, Banholzer N, Eiring P, Danhof S, Navarro-Aguadero MA, Fernandez-Martin A, Ortiz-Ruiz A, Barrio S, Gallardo M, Valeri A, Castellano E, Raab P, Rudert M, Haferlach C, Sauer M, Hudecek M, Martinez-Lopez J, Waldschmidt J, Einsele H, Rasche L, Kort?m KM. Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma. Commun Biol. 2023 12 21; 6(1):1299.
-
Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023 Dec; 4(12):1660-1674.
-
Claasen MPAW, Sneiders D, Rakk? YS, Adam R, Bhoori S, Cillo U, Fondevila C, Reig M, Sapisochin G, Tabrizian P, Toso C. European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma. Transpl Int. 2023; 36:11648.
-
Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kort?m MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F, Neri P, Bahlis NJ. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 09; 29(9):2295-2306.
-
Ji N, Tiwari AK, Yang DH. Unraveling immunotherapy's role in propelling cancer outcomes. Cancer Rep (Hoboken). 2023 07; 6(7):e1862.
-
Kirtane K, Hoogland AI, Li X, Rodriguez Y, Scheel K, Small BJ, Oswald LB, Muzaffar J, Kish JA, Bonomi M, Bhateja P, Saba NF, Steuer CE, Chung CH, Jim HSL. Patient-reported outcomes in immunotherapy for head and neck cancer. Head Neck. 2023 07; 45(7):1761-1771.
-
Zhou X, Rasche L, Kort?m KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023 04 01; 108(4):958-968.
-
Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon LB, Aldridge K, Rosasco M, Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT, Wambre E. Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy. J Allergy Clin Immunol. 2023 07; 152(1):155-166.e9.
-
Johnson DB, Atkins MB, Hennessy C, Wise-Draper T, Heilman H, Awosika J, Bakouny Z, Labaki C, Saliby RM, Hwang C, Singh SRK, Balanchivadze N, Friese CR, Fecher LA, Yoon JJ, Hayes-Lattin B, Bilen MA, Castellano CA, Lyman GH, Tachiki L, Shah SA, Glover MJ, Flora DB, Wulff-Burchfield E, Kasi A, Abbasi SH, Farmakiotis D, Viera K, Klein EJ, Weissman LB, Jani C, Puc M, Fahey CC, Reuben DY, Mishra S, Beeghly-Fadiel A, French B, Warner JL. Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. BMC Cancer. 2023 Mar 23; 23(1):265.
-
Loke P, Vickery BP, Jones SM, Peters RL, Roberts G, Koplin JJ. Food Allergen Immunotherapy in Preschool Children: Do We Have the Evidence? J Allergy Clin Immunol Pract. 2023 04; 11(4):1028-1035.
-
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T?cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2023 01 10; 56(1):93-106.e6.
-
Pierson SK, Katz L, Williams R, Mumau M, Gonzalez M, Guzman S, Rubenstein A, Oromendia AB, Beineke P, Foss? A, van Rhee F, Fajgenbaum DC. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun. 2022 11 24; 13(1):7236.
-
Kanchan K, Shankar G, Huffaker MF, Bahnson HT, Chinthrajah RS, Sanda S, Manohar M, Ling H, Paschall JE, Toit GD, Ruczinski I, Togias A, Lack G, Nadeau KC, Jones SM, Nepom GT, Mathias RA. HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success. Front Immunol. 2022; 13:941839.
-
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
-
Pashov A, Murali R, Makhoul I, Karbassi B, Kieber-Emmons T. Harnessing Antibody Polyspecificity for Cancer Immunotherapy. Monoclon Antib Immunodiagn Immunother. 2022 Oct; 41(5):290-300.
-
Fetse J, Zhao Z, Liu H, Mamani UF, Mustafa B, Adhikary P, Ibrahim M, Liu Y, Patel P, Nakhjiri M, Alahmari M, Li G, Cheng K. Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy. J Med Chem. 2022 09 22; 65(18):12002-12013.
-
Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol. 2022 08; 6:e2200049.
-
Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, Gulei D, Dima D, Tanase A, Einsele H, Ciurea S, Tomuleasa C, Caers J. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol. 2022 06 07; 15(1):78.
-
Datta R, Jones SM. Cracking the Nut: Oral Immunotherapy Conundrums. J Allergy Clin Immunol Pract. 2022 06; 10(6):1664-1665.e8.
-
Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022 04 26; 6(8):2466-2470.
-
Bess SN, Greening GJ, Rajaram N, Muldoon TJ. Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy. BMC Immunol. 2022 04 23; 23(1):20.
-
Liu H, Liu Y, Zhao Z, Li Y, Mustafa B, Chen Z, Barve A, Jain A, Yao X, Li G, Cheng K. Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy. Front Immunol. 2022; 13:838966.
-
Chen J, Barrett L, Lin Z, Kendrick S, Mu S, Dai L, Qin Z. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. J Cell Mol Med. 2022 05; 26(9):2557-2565.
-
Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. Eur J Cancer. 2022 04; 165:81-96.
-
Agarwal Y, Milling LE, Chang JYH, Santollani L, Sheen A, Lutz EA, Tabet A, Stinson J, Ni K, Rodrigues KA, Moyer TJ, Melo MB, Irvine DJ, Wittrup KD. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat Biomed Eng. 2022 02; 6(2):129-143.
-
Thakur S, Jain M, Zhang C, Major C, Bielamowicz KJ, Lacayo NJ, Vaske O, Lewis V, Murguia-Favela L, Narendran A. Identification and in vitro validation of neoantigens for immune activation against high-risk pediatric leukemia cells. Hum Vaccin Immunother. 2021 12 02; 17(12):5558-5562.
-
Paidi SK, Rodriguez Troncoso J, Raj P, Monterroso Diaz P, Ivers JD, Lee DE, Avaritt NL, Gies AJ, Quick CM, Byrum SD, Tackett AJ, Rajaram N, Barman I. Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. Cancer Res. 2021 11 15; 81(22):5745-5755.
-
Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, Riedel A, H?per S, Peter J, Walter W, Haertle L, Meggendorfer M, Topp MS, Rosenwald A, Da Via MC, Bolli N, Weinhold N, Einsele H, Haferlach C, Kort?m KM, Rasche L. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021 10 12; 5(19):3794-3798.
-
Lewis GD, Guzman AK, Haque W, McLellan BN, Teh BS. Comparison of Survival Outcomes With/Without Adjuvant Radiation Therapy in Desmoplastic Melanoma. Dermatol Surg. 2021 10 01; 47(10):1333-1336.
-
Rasche L, W?sch R, Munder M, Goldschmidt H, Raab MS. Novel immunotherapies in multiple myeloma - chances and challenges. Haematologica. 2021 10 01; 106(10):2555-2565.
-
Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021 10 11; 39(10):1375-1387.e6.
-
Chambers A, Kundranda M, Rao S, Mahmoud F, Niu J. Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Curr Oncol Rep. 2021 07 16; 23(9):100.
-
Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 09; 68(9):e29188.
-
Pasetto A, Lu YC. Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy. Front Immunol. 2021; 12:689091.
-
Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021; 12:667054.
-
Mohan M, Hari P, Dhakal B. Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. JCO Oncol Pract. 2021 07; 17(7):405-413.
-
Vyskocil S, Cardin D, Ciavarri J, Conlon J, Cullis C, England D, Gershman R, Gigstad K, Gipson K, Gould A, Greenspan P, Griffin R, Gulavita N, Harrison S, Hu Z, Hu Y, Hata A, Huang J, Huang SC, Janowick D, Jones M, Kolev V, Langston SP, Lee HM, Li G, Lok D, Ma L, Mai D, Malley J, Matsuda A, Mizutani H, Mizutani M, Molchanova N, Nunes E, Pusalkar S, Renou C, Rowland S, Sato Y, Shaw M, Shen L, Shi Z, Skene R, Soucy F, Stroud S, Xu H, Xu T, Abu-Yousif AO, Zhang J. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route. J Med Chem. 2021 05 27; 64(10):6902-6923.
-
Uson Junior PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, Borad MJ. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently? Semin Liver Dis. 2021 05; 41(2):136-141.
-
Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021 07; 16(7):1086-1098.
-
Braunstein M, Weltz J, Davies F. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. Expert Rev Hematol. 2021 04; 14(4):377-389.
-
Richter J, Ramasamy K, Rasche L, Blad? J, Zweegman S, Davies F, Dimopoulos M. Management of patients with difficult-to-treat multiple myeloma. Future Oncol. 2021 Jun; 17(16):2089-2105.
-
Ekeke CN, Russell KL, Joubert K, Bartlett DL, Luketich JD, Soloff AC, Guo ZS, Lotze MT, Dhupar R. Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. Ann Surg Oncol. 2021 May; 28(5):2715-2727.
-
Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mul? J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 04; 204(1):96-106.
-
Yasin H, Yadala V, Khan NAJ, Graffeo V, Denning K, Lebowicz Y. Immunotherapy-Induced Sarcoid-Like Reaction: A Shrewd Imitator. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211009400.
-
Kurakula M, Chen L, Tiwari AK, Srinivas NR, Dash RP, Panizzi PR, Arnold RD, Babu RJ. Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy. Crit Rev Ther Drug Carrier Syst. 2021; 38(4):1-38.
-
Scurlock AM, Burks AW, Sicherer SH, Leung DYM, Kim EH, Henning AK, Dawson P, Lindblad RW, Berin MC, Cho CB, Davidson WF, Plaut M, Sampson HA, Wood RA, Jones SM. Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research. J Allergy Clin Immunol. 2021 03; 147(3):992-1003.e5.
-
Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 12; 8(2).
-
Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, Quick CM, Galhardo EP, Dings RPM, Vang KB, Narayanasamy G, Makhoul I, Griffin RJ. Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiat Res. 2020 12 01; 194(6):688-697.
-
Rasche L, Hudecek M, Einsele H. What is the future of immunotherapy in multiple myeloma? Blood. 2020 11 26; 136(22):2491-2497.
-
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
-
Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 10; 17(10):555-570.
-
Kieber-Emmons T. The Future of Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. Monoclon Antib Immunodiagn Immunother. 2020 08; 39(4):105-106.
-
Lu YC, Wang XJ. Harnessing the power of the immune system in cancer immunotherapy and cancer prevention. Mol Carcinog. 2020 07; 59(7):675-678.
-
Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584.
-
Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020 Oct; 38(10):2537-2545.
-
Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, W?lfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, H?nemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethm?ller G, Stuhler G. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun. 2019 11 26; 10(1):5387.
-
Aydin AM, Cheriyan S, Spiess PE. Treating advanced penile cancer: where do we stand in 2019? Curr Opin Support Palliat Care. 2019 09; 13(3):249-254.
-
Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11):1366-1379.
-
Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, Birrer MJ, Wong STC, Mok SC. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clin Cancer Res. 2019 11 01; 25(21):6417-6428.
-
Kohler H, Pashov A, Kieber-Emmons T. The Promise of Anti-idiotype Revisited. Front Immunol. 2019; 10:808.
-
Kieber-Emmons T. Commentary: Metabolism Impact on Immunotherapy. Monoclon Antib Immunodiagn Immunother. 2019 04; 38(2):37.
-
Rasche L, Kort?m KM, Raab MS, Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. Int J Mol Sci. 2019 Mar 12; 20(5).
-
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 09; 33(9):2266-2275.
-
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):332-344.
-
Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79.
-
Atiq SO, Atiq OO, Atiq MO, Phillips KC, Jacks BB, Moreno M, Maraboyina S, Atiq OT. The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer. Am J Case Rep. 2018 Oct 18; 19:1241-1244.
-
DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 09; 10(12):1077-1091.
-
Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. 18F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. J Nucl Med Technol. 2018 Sep; 46(3):260-264.
-
Davies FE. Is molecular remission the goal of multiple myeloma therapy? Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):205-211.
-
Palmer BW, Harmell AL, Dunn LB, Kim SY, Pinto LL, Golshan S, Jeste DV. Multimedia Aided Consent for Alzheimer's Disease Research. Clin Gerontol. 2018 Jan-Feb; 41(1):20-32.
-
Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
-
Jones SM, Burks AW. Food Allergy. N Engl J Med. 2017 09 21; 377(12):1168-1176.
-
Jevtic S, Sengar AS, Salter MW, McLaurin J. The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Res Rev. 2017 Nov; 40:84-94.
-
Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlar C, Khan I, Doshi P, Usmani S. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):44-51.
-
Lee DE, Clark AK, Tran KA, Shi VY. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018 Jun; 29(4):364-374.
-
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017 11; 17(11):1417-1431.
-
Huang L, Russell DG. Protective immunity against tuberculosis: what does it look like and how do we find it? Curr Opin Immunol. 2017 Oct; 48:44-50.
-
Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, Lee CB, Collichio FA, Fried D, Marks LB, Chera BS. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs. 2017 07; 28(6):669-675.
-
Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer Biol Ther. 2017 Jul 03; 18(7):451-469.
-
Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017 Apr; 55:190-199.
-
Mahmoud F, Wilkinson JT, Gizinski A, Viswamitra S, Gokden N, Vander Schilden J. Could knee inflammatory synovitis be induced by pembrolizumab? J Oncol Pharm Pract. 2018 Jul; 24(5):389-392.
-
Jethava Y, Guru Murthy GS, Hamadani M. Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017 Jun; 10(2):47-56.
-
Morgan GJ, Jones JR. Integration of Genomics Into Treatment: Are We There Yet? Am Soc Clin Oncol Educ Book. 2017; 37:569-574.
-
Rodriguez A, Tatter SB. Laser Ablation of Recurrent Malignant Gliomas: Current Status and Future Perspective. Neurosurgery. 2016 Dec; 79 Suppl 1:S35-S39.
-
Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017 Dec; 23(8):620-624.
-
Atrash S, Makhoul I, Mizell JS, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. J Oncol Pharm Pract. 2017 Apr; 23(3):215-219.
-
Lu YC, Robbins PF. Targeting neoantigens for cancer immunotherapy. Int Immunol. 2016 07; 28(7):365-70.
-
Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther. 2016 06; 16(6):827-839.
-
Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84.
-
Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 06; 51(6):850-2.
-
Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016 Feb; 28(1):26-33.
-
Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016 02; 28(1):22-7.
-
Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015 Dec 11; 350(6266):1387-90.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|